Aygen, B. (2020) “Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience”, Turkish Journal of Gastroenterology, 31(4), pp. 305–317. doi: 10.5152/tjg.2020.19197.